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  ABSTRACT 
  In Iran intramuscular (IM) administration of antivenoms is used for the treatment of human scorpion envenom-
ing of six medically dangerous scorpion species, including   Odonthubuthus doriae (O. doriae ).  The  purpose 
of the current study is to investigate the efﬁ  ciency of the intramuscular route and the delay of injection on the 
neutralizing effect of the available polyvalent antivenom. We compared the pharmacokinetics parameters of 
  O. doriae   venom and its antivenom. 5  µg   131  I-labeled venom and 0.2  µl of antivenom were administered 
via subcutaneous (SC) or IM into rats. Blood samples were taken at various predetermined time intervals dur-
ing a 24  hr period for the venom and a 360  min period for the antivenom. The radio-iodination was carried 
out using the chloramin-T method. The results showed that pharmacokinetic parameters of the venom were 
T  1/2   = 496.53 min; V  d   = 1522 ml/kg; Cl = 2.12 ml/kg/min; mean resident residual time (MRT) = 555.77 min, and 
for the antivenom T  1/2   = 902.13 min, V  d   = 666.66 ml/kg , Cl = 0.512 ml/kg/min and MRT = 1292 min. The total 
body clearance of the venom is relatively low in agreement with a high mean residence time. Higher AUC and 
C  max   values for the antivenom as well as its longer residence time indicate that the venom and antivenom are 
expected to have enough opportunity to interact in the tissue compartments. Over, this study suggests that the 
intramuscular administration of a single dose of antivenom (2 vials each of 5 ml) based on current protocol in 
Iran is a suitable route for the treatment of envenomation with   O. doriae  . Prudently, further clinical studies with 
similar aims need to be carried out to conﬁ  rm these ﬁ  ndings in human victims  .   
KEYWORDS:   Iranian  scorpion ,    Odonthubuthus doriae  ,   Razi  polyvalent  antivenom ,   pharmacokinetic  parameters , 
 venom   
  INTRODUCTION 
  Scorpion envenomation has lead to the study of biochemi-
cal and pharmacological actions of the toxic components 
of scorpion venom. This has resulted in a better under-
standing of the envenomation syn  drome, and to improve 
the treatment. Antivenom immunotherapy remains the 
only speciﬁ  c treatment for scorpion envenomations. The 
optimization of toxin neutralization by speciﬁ  c antibod-
ies depends on the pharmacokinetics of both the antibody 
and the toxin molecules, and the capacity of the speciﬁ  c 
anti  bodies to sequester the toxin. Thus, the improve  ment 
in immunotherapeutic envenomations requires a bet-
ter understanding of scorpion venom pharmacokinetics 
( Kriﬁ   et al, 2005  ). 
  Experimental toxicokinetic studies of   Androctonus 
amoreuxi ,   Tityus serrulatus ,   Buthus occitatanus tunet-
anus ,   Leiurus quinquestriatus ,   Buthotus judaicus , 
  A. mauretanicus mauretanicus   and   A. crassicauda  
radiolabeled venom have been performed after intrave-
nous or subcutaneous injections in rabbit, guinea-pig 49
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of   131  I was added to 30 µl of deionized H  2  O. Then the fol-
lowing solutions were added in sequence: 3.5 mg of venom 
in 300 µl of 0.5 M phosphate buffer, pH 7.2-7.4, 100 µl of 
6 mg/ml chloramine-T; and 100 µl of 6 mg/ml sodium met-
abisulﬁ  te. Buffers were used to control the pH of solution 
for optimum efﬁ  ciency of the proteins. To separate unin-
corporated   131  I from the iodinated venom, a column packed 
with Sephadex G50 (  Penefsky, 1979  ) collected the labeled 
venom in 1 ml fractions.   
  Blood  Sampling 
  Six groups, consisting of three rats each, were sacri-
ﬁ  ced at 10, 20, 40, 60, 120, 360 and 1440  min following 
SC administration of 5  µg venom supplement with trace 
amounts of   131  I. The same groups of rats were sacriﬁ  ced at 
5, 10, 40, 60, 120 and 360  min following IM administra-
tion of 0.2  ml available antivenom supplement with trace 
amount of   131  I. The rats received water and food   ad libitum . 
The time course of venom concentration in the plasma was 
followed by radioactivity. Samples of whole blood were 
collected in tubes containing ethylenediaminetetraacetic 
acid (EDTA) as anticoagulant (ﬁ  nal concentration 0.05 M), 
immediately before and at regular time intervals after the 
end of the administrations. The concentration of scorpion 
  131 I-labeled   O. doriae   venom in plasma was determined 
after trichlroacetic acid (TCA) precipitation. Plasma samples 
(50-100 µl)  were added to 450 or 400 µl of immunoglobu-
lin from horses and then precipitated with 500  µl of 20% 
(v/v) TCA. After a 30-60 min incubation period, mixtures 
were centrifuged for 15  min, and the radioactivity was 
mea  sured in the pellet in a γ-counter (Pharmacia, Uppsala, 
Sweden). The results are presented as percent injected 
dose/ml blood. The percent radioactivity data were pre-
sented after conversion to ng/ml. 
   Determination  of  pharmacokinetic  parameters 
  The plasma concentration vs time data was subjected to a 
non-compartmental pharmacokinetic analysis to obtain an 
estimate of various pharmacokinetic parameters, such as 
total body clearance (CL/F), distribution volume (V  d /F), 
area under the curve (AUC), and mean residence time 
(MRT). The area under the plasma concentration versus the 
time curve (AUC) was calculated using the linear trapezoi-
dal rule with extrapolation to inﬁ  nity. Cl/F, MRT and V  ss/F  
were calculated using the following non-compartmental 
equations (  Kriﬁ   et al, 2005  ): 
 MRT  = AUMC/AUC 
  Cl/F = Dose/AUC 
 V ss   = Cl/F x MRT 
  Whereas, AUMC (area under the ﬁ  rst  moment 
curve) is the area under the Cxt plotted against   t   from time 
0 to inﬁ  nitive. 
   Statistical  analysis 
  All values were presented as mean ± standard deviation. The 
means were calculated from at least three separate experi-
ments. The signiﬁ  cance of the data was analyzed by the 
two-tailed unpaired or paired Students’ test. The level of 
signiﬁ  cance was set at P < 0.05. 
and rat models (  Ismail et al, 1980  ;   Ismail et al, 1992  ; 
  Ismail et al, 1994  ;   Revelo et al, 1996  ;   Ismail et al, 1998  ; 
 Kriﬁ    et al, 2001  ; El Hafny et al, 2002). Most of these 
studies used employed measurement of radioactivity levels 
in blood, which showed bi- or tri-compartmental pharma-
cokinetics depending upon the scorpion species and the 
injection route. 
  The Iranian polyvalent antivenom is produced by the Razi 
Vaccine and Serum Production and Research Institute 
through the immunization of horses against the 6 medically 
important scorpion species in Iran:   O. doriae, Mesobuthus 
eupeus, Androctonus crassicauda, Buthotus (Hottentota) 
Saulcyi, Buthotus sach   and   Hemiscorpius lepturus   ( Latiﬁ   
and Tabatabai, 1979  ). The antivenom contains a dilution of 
the F(ab′)  2   fraction of equine immunoglobulins obtained 
after double saline precipitation and pepsin digestion. 
  However, to-date no information of pharmacokinetic para-
meters of the Iranian scorpion venom and Razi Institute 
polyvalent antivenom is available. Currently, the scorpion 
sting victims in Iran, including those of   O. doriae   sting, are 
treated with intramuscular administration of antivenom. 
The scope of the present study is to determine the pharma-
cokinetics of the   O. doriae   venom in experimentally enven-
omed rats as well as the pharmacokinetics of the available 
antivenom to evaluate, or optimize, the available therapies 
and routes of administration.   
  MATERIALS AND  METHODS 
  Animals 
  The male rats weighing 250-300 gm were from Razi Insti-
tute (Karaj, Tehran). All pharmacokinetic experiments were 
conducted in accordance with principles and guidelines of 
the “European Convention for the Protection of Vertebrate 
Animals Used for Experimental and other Scientiﬁ  c Pur-
poses and the Guiding Principles in the Use of Animals in 
Toxi  cology” which were adopted by the Society of Toxicology 
in July1989 and revised in March 1999. 
   Materials 
  The CNBr-activated Sepharose and Sephadex G  50   were pur-
chased from Pharmacia (Uppsala, Sweden). CM-Sepharose 
was from Sigma (St Louis, MO, USA). Sodium dodecyl 
phosphate, Hydrogen peroxide, potassium phosphate buffer, 
sulforic acid, sodium sulfate, phenylenediamine and Tris-
buffer were from Merck (Darmastadt, Germany). The Agar 
gel and immuno  globulin fragments against scorpion from 
horse were purchased from Razi institute (Karaj, Iran). 
  O. doriae   lyophilized venom and antivenom were prepared 
in Razi institute. Venom was collected by electrical stimula-
tion, extracted with water, freeze-dried and stored at -20  o C 
until further use (  Miranda et al, 1970  ). 
      Radioiodination of the venom and antivenom 
  Radio-iodination of venom and antivenom were carried 
out using the chloramin-T method. This method speciﬁ  -
cally iodinates tyrosine residues in proteins forming a 
stable covalent protein-  131  I bond. The method is generally 
accepted to be mild enough so as not to affect the activ-
ity of the protein being labeled (  Hunter and Greenwood, 
1962  ;   Greenwood et al, 1963  ). Brieﬂ  y, 0.3  mCi (300  µl) 50
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the antivenom, and on the kinetics of both the venom and 
anitvenom to move from the extravascular compartment to 
the vascular ones, or possibly both. The antivenom used in 
serotherapy should possess pharmacokinetic characteristics 
enabling it to distribute rapidly enough to neutralize the 
venom fraction distributed to tissues. Pharmacokinetics 
contributes to the understanding of the relationship between 
dose and response in the design of new therapies and/or 
modiﬁ  cations of the current medicinal products. 
  Most of the reported scorpion venom pharmacokinetic 
studies were performed using   125  I-labeled venom (  Ismail 
and Abd-Elsalam, 1988  ;   Ismail et al, 1994  ;   Revelo et al, 
1996  ; Calderone-Aranda et al, 1999) or by following toxin 
concentration by ELIZA (  Revelo et al, 1996  ;   Santana et al, 
1996 ;  Kiriﬁ    et al, 2001; El-Hafney et al, 2002). In the 
current study, venom pharmacokinetics was followed by 
measuring TCA perceptible radiolabeled toxins in experi-
mentally envenomed rats. Indeed, after the injection, the   
in vivo   degradation of radioiodinated venom proteins could 
yield toxin fragments and/or free radioactive iodine, which 
might bind non-speciﬁ   cally to the plasma proteins still 
measured by this method. The free and non-speciﬁ  c plasma 
radioactivities and/or the degraded radio labeled venom 
toxins are still being quantiﬁ  ed by the radioactive method; 
while ELIZA could not detect those. The ELISA assay 
could present limitations and disadvantages, such as the 
relative insensitivity, the failure to detect the venom antigen 
by slight modiﬁ  cation in the body and the antibody bind-
ing sites are mostly different from the pharmacologic active 
ones,   etc  . These disadvantages could be limited by an accu-
rate standardization of the assay (  Kriﬁ   et al, 2001  ). 
  In the present study, 5  µg   O. doriae   venom and 0.2  ml 
antivenom were administered via SC and IM, respectively. 
The adjusted dose of venom, as the result of a scorpion sting, 
was the same as the amount that was injected. Also, 0.2 ml 
of the antivenom injection was adjusted to the rats, since in 
the current Iranian protocol, 2 vials of 5  ml antivenom are 
recommended for an adult. 
  As shown in   Tables 1   and   2   the volume of distribution of 
antivenom was 666 ml/kg, which is signiﬁ  cantly lower com-
pared to the V  d   of venoum determined after SC injection 
(1522 ml/kg).  Considering  the T  max   values, the venom was 
    RESULTS 
  Pharmacokinetics  of  the   O. doriae   venom  
  The result of the pharmacokinetic analysis, performed in 
three groups of rats after SC injection of the 5  µg venom 
dose, are shown in   Figure 1  , and the corresponding pharma-
cokinetic parameters are noted in   Table 1  . The time to reach 
the maximal venom concentration in the blood, Tmax, was 
virtually brief (about 2 hr) and the apparent terminal half-life 
was 496 min. 
          The pharmacokinetics of the venom showed that after a 
rapid ascending phase, which means a fast absorption of 
scorpion toxins, the toxin concentrations in plasma reached 
a maximal value (C  max )  after T max   of 120 min. Then the curve 
followed a rather slow bi-phasic decline, followed by a slow 
and a more slowly declining phase (  Figure 1  ). 
    Pharmacokinetics of the antivenom 
  Pharmacokinetic parameters of antivenom determined after 
an IM injection of antivenom by measurement of radioac-
tivity method are shown in   Table 2  . AUC  last   and  C max   were 
at about 14  x and 3  x higher, respectively, in antivenom 
pharmacokinetic if compared with venom values. The C  max  
was reached earlier in antivenom (T  max   = 60 vs 120 min). V  d  
and MRT of antivenom were lower and higher, respectively, 
than venom in the pharmacokinetic parameters obtai  ned. 
The time course of antivenom concentration in plasma, 
determined by radioactivity measurements, showed a 
bi-exponential decline (  Figure 2  ), indicating that the 
antivenom was distributed into two compartments with a 
terminal half-life (t  1/2  ) of 496.43 min.         
 DISCUSSION 
  Despite the development of improved antivenom prepara-
tions and the conviction widely shared among clinicians 
that the antivenom therapy is the most effective treatment 
of severe cases of scorpion envenomations, the use of such 
speciﬁ  c treatment is still justiﬁ  ed mainly on the basis of 
empirical observations. The knowledge of the neutraliza-
tion capacity and kinetics of scorpion venom and antivenom 
can contribute to the improvement of the treatment strate-
gies. Achieving such a goal is directly dependent upon the 
efﬁ  cacy of speciﬁ  c bindings of the circulating toxins to 
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  Figure 1.      Plasma  concentration-
time proﬁ  le of venom after SC 
administration of 5 µg of   O. doriae  
venom supplemented with trace 
amount of radiolabeled   131  I. Data are 
reported as means ± SEM (N = 3).   51
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 Furthermore,   131  I-antivenom showed higher C  max   and AUC last  
values and an earlier T  max   following the IM administration, 
indicating a faster absorption and higher uptake than the 
venom. The increased uptake of the antivenom can also be 
explained on the basis of a higher absorption rate for the 
antivenom, explaining the lower value found for T  max  . It is 
noteworthy that the values of the AUC determined after the 
IM administration of 5  µg venom are close to those pre-
sented by Kriﬁ   and colleagues study that used the IV route. 
  With regards to the antivenom, we found an elimination 
half-life of 15  hr after IM injection, which is signiﬁ  cantly 
longer than the reported values for the intravenously admin-
istered   Andrectonus mauretanicus mauretanicus   ( El-Hafny 
et al, 2002  ),   C. limpidus limpidus   (  Calderon-Aranda et al, 
1999  ) and   B. occitanus mardoche   (Pepin-Covatta et al, 1996) 
antivenoms. Furthermore, the AUC determination of the 
antivenom is higher than that of the venom, which differs 
signiﬁ  cantly. Therefore, these observations indicate a com-
plete absorption of antivenom (and/or venom) from its injec-
tion site. 
 The  V d   indicating a fast distribution of the venom into 
tissues occurred in a large extravascular compartment. 
As expected, the V  d  /F for the venom was higher indicat-
ing a possible increased distribution. The Cl  F   of venom was 
2.12 ml/kg/min, indicating its rapid elimination. These ﬁ  nd-
ings suggest a fast clearance of the scorpion toxins in the 
experiments performed with radioactive toxins. The rapid 
absorption of venom may be due to the low molecular 
weight toxins (4-7 kDa) of this scorpion (  Jalali et al, 2005  ; 
  Abdel-Mottaleb et al, 2006  ;   Abdel-Mottaleb et al, 2008  ). 
The fast absorption and distribution of the venom indicate 
that   O. doriae   envenomation is rapid. Therefore, speciﬁ  c 
and symptomatic treatments must be started as soon as pos-
sible after the sting, or else at least as soon as envenomation 
symptoms appear. 
  In a randomized controlled trial of scorpion antivenom 
therapy in Tunisia it was shown that the serotherapy 
against   Buthus occitanus tunetanus   scorpion was inefﬁ  -
cient (  Abroug et al, 1999  ). Although, this investigation was 
Table 1. Phamacokinetic parameters of O. doriae venom 
determined after sc injection of 5 µg/ml venom in rat.
Toxicokinetic parameters 
of venom
Value
(mean ± SEM)
Tmax (min) 120 ± 8
Cmax (ng/ml) 16.42 ± 3.2
AUClast (ng/min/ml) 11175 ± 652
THalf life (min) 496.53 ± 46
AUCINF (ng/min/ml) 503.486 ± 46
Vd/F (ml/kg) 1522 ± 135
Cl/F (ml/kg/min) 2.12 ± 0.2
MRT (min) 555.77
Table 2. Phamacokinetic parameters of antivenom determined 
after IM injection of 0.2 ml of Razi polyvalent antivenom in rat. 
Toxicokinetic parameters 
of antivenom
Value
(mean ± SEM)
Tmax (Min) 60 ± 6
Cmax (ng/ml) 48.9 ± 4.6
AUClast (ng/min/ml) 147962.5 ± 24356
THalf life (min) 902.13
AUCINF (ng/min/ml) 2500.19 ± 325
Vd/F (ml/kg) 666.66 ± 115
Cl/F (ml/kg/min) 0.512 ± 0.08
MRT (min) 1292.87
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    Figure 2.      Plasma 
concentration-time proﬁ  le 
of antivenom F(ab′)2 after 
intramuscular administration 
of 0.2 ml of antivenom sup-
plemented with trace amount 
of radiolabeled   131 I- O. doriae  
venom to rat. Data are reported 
as means ± SEM (N = 3).   
absorbed slowly compared to the antivenom and its maxi-
mal concentration reached 1  hr after the antivenom. This 
slow absorption may explain the delay onset of the clinical 
signs after an   O. doriae   sting. The antivenom F(ab′)2 had a 
higher rate of entry into the systemic circulation and a more 
extended elimination half-life. Thus, it is anticipated that 
antivenom would efﬁ  ciently neutralize the venom following 
the administration of IM. 52
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conducted on a small number of severely envenomed 
patients, it raises the question whether the dose of antivenom 
administered was less than the minimal required for neutral-
izing the toxic manifestations of the venom. 
  The IM route is still used in immunotherapy of scorpion 
envenoming. However, it is important to note that it results 
in a delayed neutralization of toxins that is 10-fold lower 
efﬁ   cacy compared to the intravenous route (  Ismail and 
Abd-Elsalam, 1998  ). Ismail and Abd-Elsalam concluded 
the IM injection of antivenoms is certainly ineffective 
in neutralizing the action of venoms, as the venoms and 
antivenom have no opportunity to meet quickly enough in 
the central or tissue compartments. But in this current study, 
the efﬁ  cacy of used intramuscular route, dose and antici-
pated delay for antivenom administration indicate efﬁ  ca-
cious of immunotherapy with Razi antivenom. In support 
of this,   Pe´pin-Covatta et al (1996)   reported that less than 
40% of the intramuscularly injected antivenom F (ab′)2 are 
slowly absorbed from the injection site. 
  Iranian epidemiological data shows that 30% of the patients 
were taken to medical facilities more than 3  hr after being 
stung by the scorpion,   H. lepturus   – considered as the most 
dangerous scorpion in Iran (  Pipelzadeh et al, 2007  ;   Jalali 
et al, 2010  ). In other studies, a maximum distribution of 
the toxins and their complete neutralization in plasma were 
observed when the minimal efﬁ  cient antivenom dose was 
injected 4-6  hr after the envenomation. However, it is dif-
ﬁ  cult to predict the clinical results of an antivenom immu-
notherapy when performed a long time after envenomation. 
Indeed, it is quite possible that the scorpion toxins may exert 
their deleterious effects and cause an irreversible damage 
before the administration of the antivenom. 
   CONCLUSIONS 
  •   Immediate intramuscular administration of a dose of 
antivenom (human values corrected in experimental 
rat) has a favorable proﬁ  le from kinetic and measured 
data view. 
  •   The intramuscular route administration of antivenom 
may be considered appropriate when administered 
within the gold time of 2 hr. 
  •   IM injection may be suitable route for neutralization 
of   O. doriae   toxins with the available polyvalent 
antivenom prepared in the Razi Institute. 
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